Turnover
≈ €42,000 estimated
The micro format states no turnover.
BioStabImpact
Lifetime
1 annual account with figurespeak €9,307 (2025)
€9,307
peak €1,414 (2025)
€1,414
peak €4,414 (2025)
€4,414
€24,375
Board1 name since 2025
1 directorRYELANDT Damien Vincent
Documentsfilings and deeds
10-07-202621 days before the deadline
2025micro format
Incorporation 20-021 establishment registeredFirst year with figures
Key points
from the 2025 annual accountsDebts
€24,375 85% of the balance sheet
Suppliers 67%Taxes and wages 33%
Position in the sector
€4,414
Less equity than 87% of companies in architecture and engineering. Sector median €63,879 · 11,799 companies.
Checked score
89
Excellent
Financially stronger than 24% of micro companies in architecture and engineering (NACE 71)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.1% across 14,828 companies (NACE 71, micro).
About 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
03-2026: 0.5%
04-2026: 0.5%● unchanged vs 03-2026
05-2026: 0.5%● unchanged vs 04-2026
06-2026: 0.5%● unchanged vs 05-2026
07-2026: 0.5%● unchanged vs 06-2026highest value
08-2026: 0.1%▼ -0.4 percentage points vs 07-2026lowest value
09-2026: 0.1%● unchanged vs 08-2026
10-2026: 0.1%● unchanged vs 09-2026
11-2026: 0.1%● unchanged vs 10-2026
Financial strengthAverage
Score breakdown
raises risk
Founded in 2025
lowers risk
Sector: Architectural and engineering activities; technical testing and analysis (NACE 71)
Liquidity: current ratio 0.60, cash €7,001
Size: total assets €28,789
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 71, micro). It does better than 19% of them on solvency, 15% on liquidity and 40% on profitability.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 294 companies had the same profile as BioStabImpact has now. Each dot is one company, two years later.
95.6%
were still trading
2.0%
stopped another way
2.4%
went bankrupt
The bankruptcy probability of BioStabImpact itself is lower: 0.1% within 12 months. It rests on far more data about BioStabImpact than the profile alone.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 294 companies, not a prediction for BioStabImpact. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 18% of 11794 sector peers (2025).
NBB · sector comparisonPosition among 11794 sector peers
Solvency
better than 18%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-07-2026, 21 days ahead of the deadline.
NBB · 1 filingDeviation from the deadline
2025
21 days early
← before the deadline
after the deadline →
Searched, nothing found (1)
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:1020144644
Incorporation
Founding capital of €3,000, 100 shares · Founder: RYELANDT Damien Vincent · Appointment: RYELANDT Damien Vincent (director) · published on 20-02-2025 · Gazette deed
First establishment
Rue Champ Rodange 55, Waterloo
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| BioStabImpact Waterloo | €28,789 | €9,307 | 15.3% | - |
| Vi.BE Ingénieur Conseil Ouffet | €33,276 | €10,595 | 21.9% | - |
| Blue-C Leuven | €32,887 | €8,985 | 88.2% | - |
| A&BI ENGINEERING Liège | €26,516 | €8,832 | 37.4% | - |
| JUNOVA TECH Namur | €23,909 | €11,346 | 50.7% | - |
| MB expertises Erquelinnes | €20,483 | €10,186 | 43.9% | - |
| VO-TECH Oosterzele | €26,304 | €12,649 | 36.9% | - |
These companies have the same main activity as BioStabImpact: engineering and related technical consultancy, excluding land surveyors (NACE 71121). They are comparable in size and age: total assets between €20,500 and €33,300, founded between 2024 and 2025.
Official details
Source: KBO- Status
- Active since 18-02-2025Normal situation
- Activity
- Engineering and related technical consultancy, excluding land surveyorsNACE 71121and 5 others
- Establishment unit
- 2.370.458.9771410 Waterloo, since 18-02-2025
- Financial year end
- 31 December
- Peppol
- Reachable since 09-12-2025
Annual accounts 2025
- €28,789
- Filing
- Filed on 10-07-2026, 21 days before the end of the filing period
Insights on BioStabImpact
BioStabImpact has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €4,414 and a net result of €1,414.
Its solvency ranks better than 18% of 11,794 sector peers (NACE 71, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about BioStabImpact
- What is the company number of BioStabImpact?
- The company number of BioStabImpact is 1020.144.644. The VAT number is the same number with BE in front: BE 1020.144.644.
- Where is BioStabImpact based?
- The registered office is at Rue Champ Rodange 55, 1410 Waterloo.Company details
- What does BioStabImpact do?
- According to the KBO register, the main activity is engineering and related technical consultancy, excluding land surveyors (NACE 71121).
- What is the legal form of BioStabImpact?
- BioStabImpact is a private limited company (BV).
- When was BioStabImpact founded?
- BioStabImpact was founded on 18-02-2025.
- Is BioStabImpact still active?
- Yes, BioStabImpact is an active enterprise in the KBO register.
- What is the turnover of BioStabImpact?
- The turnover in financial year 2025 is ≈ €42,000. This figure is estimated from the gross margin of €9,307 and 30 comparable companies (NACE 71121). It probably lies between €29,000 and €79,000. It is a rough estimate.Financials
- Is BioStabImpact profitable?
- In financial year 2025, BioStabImpact made a profit of €1,414.
- Where can I find the annual accounts of BioStabImpact?
- BioStabImpact filed 1 annual account with the National Bank of Belgium, for financial year 2025.
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark Estimate what this company is worth.Value indication
See how customers, suppliers and banks see your own company and what to improve first.